Hold JNJ: Empirical record rejects Underweight despite rich valuation; tactical trim discipline replaces directional commitment
Maintain JNJ core position with Hold rating. The neutral analyst's 15% trim prescription (vs. aggressive 25-35% from conservative) on better execution triggers is empirically calibrated. The risk-reward is approximately symmetric: 4-6% upside to $285-290 on confirmed breakout versus 6.4% downside to $255.52 and 15.4% to $230.86 on cascading failure. However, conditional probabilities tilt bullish given the 86% Polymarket no-cut probability and defensive rotation tailwind. Scale trim magnitude to tail probability minus bounce-fade probability, not candle severity. Prior reflections converge on: maintain core, be patient on adds, trim modestly on better signals, tighten stops on closes. Price target $275.0 reflects measured move validation rather than aggressive extension.
| Position | Action |
|---|---|
| Confirmed failure above $274.65 within three sessions | Trim 10-15% of position |
| Pullback to 10 EMA near $267 that fails to bounce | Trim 10-15% of position |
| Weekly close below $255.52 with volume expansion | Downgrade to Underweight; exit remaining position |
| Clean daily close above $274.65 on volume >7.5M shares | Upgrade to Overweight; add to position |
| Pullback to $255-262 zone with RSI >45 and no MACD bearish crossover | Upgrade to Overweight; add to position |
JNJ is a compounding fortress with accelerating Q2 fundamentals, proven patent-cliff navigation via M&A, and a technical/macro setup that is actively rewarding its defensive profile — making any pullback to the $267–$270 zone a high-confidence entry.
| Indicator | Value | Signal |
|---|---|---|
| Price Close | $273.04 | neutral |
| Price Open | $269.74 | neutral |
| Price High | $273.98 | neutral |
| Price Low | $268.57 | neutral |
| Volume | 5,411,856 | neutral |
| 10 EMA | 267.13 | bullish |
| 50 SMA | 255.52 | bullish |
| 200 SMA | 230.86 | bullish |
| RSI (14) | 64.31 | bullish |
| MACD Line | 4.45 | bullish |
| MACD Signal | 3.59 | bullish |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Pullback to $255-262 zone with RSI >45 and no MACD bearish crossover
Then: Upgrade to Overweight
EV: +$285–$290 (measured-move target on clean close above $274.65 upper Bollinger Band) · concedes: TTM PE of 31.7x is a real number (though distorted by 2024 talc litigation charges); Stelara patent erosion is real (though already being offset by Tremfya, Tecvayli, Caplyta, and broader pipeline); Talc litigation remains unresolved (though $5.5B proposed settlement is a known capital cost); Leverage rose from $7.5B (2023) to $28.6B (Q2'26) due to M&A (though still only 0.82x net debt/EBITDA); PEG of 4.73 reflects muted growth relative to price (though JNJ's value is in durable compounding, not double-digit growth); Stock is near 52-week high of $276.47 (though RSI at 64 is not extended like the prior 73–74 reading)
JNJ is a late-cycle, fully-priced defensive trading at a 22.18x forward PE (20-40% premium to its historical 16-18x) with negative tangible book value (-$11.7B), an active Stelara patent cliff in year one of erosion, a proposed (not closed) $5.5B talc settlement, a balance sheet leveraged 4x in 2.5 years ($7.5B to $28.61B net debt), and a late-stage topping technical pattern — with no margin of safety for the execution risks that remain.
EV: -4% (rotation to 20 SMA at $262.50 from current ~$273) · concedes: JNJ is a high-quality, defensive franchise; Q2'26 revenue did grow 6.6% YoY; Underlying operating cash flow growth of ~5% CAGR is healthy; Dividend yield and dividend-King status provide some floor; Tremfya, Tecvayli, and Caplyta are genuine assets with revenue potential; The $5.5B talc settlement proposal is at least an attempt to resolve the overhang; Technical indicators (RSI 64.31, MACD +0.85) show near-term momentum is positive
→ vs conservative: Bear case metrics (22.18x forward PE, 4.73 PEG) are math artifacts dividing depressed earnings by truncated growth window, not valuation signals; stripping litigation distortion reveals reasonable pricing for 25.7% ROE business
→ vs conservative: $5.5 billion talc settlement proposal is overhang removal and confidence infusion, not a new liability to be treated as risk
→ vs neutral: Calling 273.04 close on 5.4M volume 'late-stage consolidation' misses the bull flag structure entirely; the pattern is coiling for breakout, not resolving
→ vs neutral: Trim plan targeting 274.65-276.47 'better exit levels' actually monetizes into the very resistance that opens 285-290 measured-move targets; trimming forfeits asymmetric upside
| MACD Histogram | +0.85 | bullish |
| Bollinger Middle (20 SMA) | 262.50 | neutral |
| Bollinger Upper | 274.65 | bearish |
| Bollinger Lower | 250.36 | bullish |
| ATR (14) | $5.83 | neutral |
Support: 267.13 · 262.5 · 255.52 · 250.36 | Resistance: 274.65 · 280 · 285 · 290
JNJ technical picture is decisively bullish with all three major moving averages positively stacked (10 EMA > 50 SMA > 200 SMA), confirming an established uptrend that began in early June 2026. Price at $273.04 is pressing the upper Bollinger Band at $274.65—a tactical resistance zone where failure to sustain a clean daily close above could precede short-term consolidation toward the 20 SMA at $262.50. Momentum is rebuilding rather than overextended; RSI at 64.31 remains below the 70 overbought threshold, and MACD histogram has risen from -1.77 (July 21) to +0.85, signaling healthy trend continuation potential. Preferred entry zones are pullbacks to $267–$270 (10 EMA area), with invalidation below the 50 SMA at $255.52.
Market Cap
$657.99 B
PE Ratio (TTM)
31.68
Forward PE
22.18
PEG Ratio
4.73
Price to Book
7.74
EPS (TTM)
$8.62
Forward EPS
$12.31
Dividend Yield
1.98%
Beta
0.231
52-Week High
$276.47
52-Week Low
$173.33
50-Day Avg
$254.83
200-Day Avg
$231.81
Book Value
$35.28
Revenue (TTM)
$97.93 B
Gross Profit
$66.73 B
Gross Margin
~68.1%
EBITDA
$34.87 B
Net Income (TTM)
$21.04 B
Operating Margin
29.2%
Profit Margin
21.5%
ROE
25.7%
ROA
8.6%
Revenue 2022
$79.99 B
Revenue 2023
$85.16 B
Revenue 2024
$88.82 B
Revenue 2025
$94.19 B
Net Income 2022
$17.94 B
Net Income 2023
$35.15 B
Net Income 2024
$14.07 B
Net Income 2025
$26.80 B
Diluted EPS 2022
$6.73
Diluted EPS 2023
$13.72
Diluted EPS 2024
$5.79
Diluted EPS 2025
$11.03
Operating Margin 2022
26.3%
Operating Margin 2023
25.8%
Operating Margin 2024
23.9%
Operating Margin 2025
27.2%
Q2 2026 Revenue
$25.31 B
Q2 2026 Operating Income
$7.17 B
Q2 2026 Net Income
$5.53 B
Q2 2026 Diluted EPS
$2.27
Q2 2026 Operating CF
$8.62 B
Q2 2026 FCF
$7.30 B
Total Assets
$201.06 B
Total Liabilities
$116.09 B
Stockholders' Equity
$84.97 B
Total Debt
$49.04 B
Net Debt
$28.61 B
Cash & Equivalents
$20.42 B
Current Ratio
1.089
Debt-to-Equity
0.577
Working Capital
$4.88 B
Goodwill + Intangibles
$96.71 B
Net Debt / EBITDA
~0.82x
Operating CF 2022
$21.19 B
Operating CF 2023
$22.79 B
Operating CF 2024
$24.27 B
Operating CF 2025
$24.53 B
CapEx 2022
$4.01 B
CapEx 2023
$4.54 B
CapEx 2024
$4.42 B
CapEx 2025
$4.83 B
FCF 2022
$17.19 B
FCF 2023
$17.78 B
FCF 2024
$18.06 B
FCF 2025
$19.31 B
FCF (TTM)
$16.89 B
Dividends Paid 2022
$11.68 B
Dividends Paid 2023
$11.77 B
Dividends Paid 2024
$11.82 B
Dividends Paid 2025
$12.38 B
Buybacks 2022
$6.04 B
Buybacks 2023
$5.05 B
Buybacks 2024
$2.43 B
Buybacks 2025
$5.95 B
2025 Business Acquisitions
$17.54 B
Q2 2025 Acquisition
$14.46 B
Q4 2025 Acquisition
$3.08 B
Strengths
Concerns
JNJ is a fundamentally elite, diversified healthcare conglomerate (Innovative Medicine + MedTech) that generated $97.93B TTM revenue and $21.04B net income with best-in-class 29.2% operating margin and 25.7% ROE. Q2 2026 demonstrated accelerating momentum with record $25.31B revenue (+6.6% YoY), $7.17B operating income, and $7.30B FCF (+122% YoY), driven by strong MedTech and CNS portfolio growth from the Intra-Cellular acquisition. The AAA-rated fortress balance sheet supports 60+ years of dividend growth (1.98% yield) with 0.82x net debt/EBITDA, though net debt has risen to $28.61B following $17.54B in 2025 acquisitions focused on offsetting Stelara/Imbruvica patent cliffs. Valuation is mixed: TTM PE of 31.68x is elevated due to 2024 trough earnings, but forward PE of 22.18x and expected EPS recovery to $12.31 provide reasonable support at current levels near the 52-week high. Recommendation bias is HOLD with positive fundamental view; constructive on pullbacks toward the 200-day MA (~$231.81).
Macro: Hawkish Fed consensus: Polymarket prices 86% probability of zero Fed rate cuts in 2026 ($7.5M volume, +1.2pp WoW); U.S. recession odds at 8% by end-2026 ($1.7M volume). Bond yield sell-off driving risk-off positioning: gold settled at $4,640.80/oz (+0.36%) and silver up 18%+ MoM. Middle East uncertainty ("lack of clarity over progress") weighing on risk appetite. GuruFocus (Aug 23) notes "Healthcare is attracting defensive capital while technology valuations face another violent reset" — defensive rotation is the dominant cross-asset theme.